Abstract Library

#4116 A review of the Scottish national Peptide Receptor Radionuclide Therapy (PRRT) service with focus on patients with small bowel neuroendocrine tumors (SBNET) treated between April 2019 and March 2021

Introduction: Scottish National PRRT Service delivers 177Lu-Dotatate nationally at the Beatson West of Scotland Cancer Centre (BWoSCC). The NETTER-1 trial (Strosberg et al 2017) significantly changed the treatment and management of patients with gastroenteropancreatic NET (GEPNET). 177Lu-Dotatate demonstrated superiority in progression free survival (PFS) in patients with G1 and 2 midgut neuroendocrine tumors (NET). 177Lu-Dotatate 7.4 GBq 8 weekly gave 65% estimated progression free survival (PFS)at 20 months versus 10.8 % with 60mg octreotide intramuscularly 4 weekly (Strosberg et al 2017). Prior to this study everolimus was the most common 2nd line treatment for SBNET with a PFS of 14 months (Puscuddo et al 2017).

Conference:

Presenting Author:

Authors: Wotherspoon I, Charlick A, McIntosh D, Reed N,

Keywords: NETTER-1, Scottish PRRT Service,

#3536 Comparison of drug sensitivity profiles of various NEN spheroids

Introduction: Neuroendocrine neoplasms (NENs) are rare cancers that arise from neuroendocrine cells. NENs are classified as well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). Small bowel and pancreatic NETs (SBNET & PNETs) are generally slow-growing but commonly metastasize to the liver and become aggressive cancers. Little is known about the drug sensitivity profile of these 3 NENs due to the lack of cellular and animal models of these malignancies. Recently, we have developed a protocol to culture NEN cells from patient tumors as patient-derived spheroids (PDS) and showed expression of NEN markers. The rarity and slow growing features of these spheroids have been hindering drug screens with many compounds.

Conference:

Presenting Author: Ear P

Authors: Tran C, Luis B, Sherman S, Mudd J, Abusada E,

Keywords: NET, NEC, spheroid, drug screening, PDX model,

#3326 Drug sensitivity profiles of PNET, SBNET and NEC spheroids

Introduction: Neuroendocrine neoplasms (NENs) are rare cancers that arise from neuroendocrine cells. NENs are classified as well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). Few mutations have been identified for NETs from the small bowel (SBNETs) and pancreas (PNETs). SBNETs and PNETs are generally slow growing but they commonly metastasize to the liver and can become aggressive cancers. NECs often harbour mutations in key cell cycle genes (TP53 and RB) and are highly proliferative. Little is known about the drug sensitivity profile of SBNET, PNET and NECs due to the lack of cellular and animal models of these malignancies. Recently, we have developed a protocol to culture NET and NEC cells from patient tumors as patient-derived spheroids and showed that they express NEN markers.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Ear P

Authors: Ear P, Tran C, Li G, Abusada E, Mudd J,

Keywords: PNET, SBNET, NEC, drug testing, spheroids,

#3211 Microscopic resection margin status does not predict long-term survival in small bowel neuroendocrine tumors

Introduction: Small bowel neuroendocrine tumors (SBNETs) are increasing in incidence and are the most common small bowel malignancy. The characteristic nodal mass, which may extend high into the mesentery, can make achieving microscopically negative resection margins difficult without resecting excessive lengths of small bowel.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Mentor K, Ammar K, Thakkar R, Farrington E, Buckley E,

Keywords: small bowel, grading, resection margin, survival,

#3058 Diagnosis and Assessment of Effectiveness of Surgical Resection of Small Bowel Neuroendocrine Tumours: The Roles of Circulating MicroRNAs

Introduction: MicroRNAs (miRNA) are small noncoding RNA molecules implicated in the pathophysiology of myriad neoplasms. Clinically useful biomarkers are needed in SB NET to ascertain disease aggressiveness, select treatment strategy, detect early recurrence and monitor response.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Clift A

Authors: Malczewska A, Frampton A, Prado M, Ameri S, Dabrowska A,

Keywords: neuroendocrine, small bowel, intestine, microRNA, biomarker,